AcelRx Pharmaceuticals (NASDAQ:ACRX) Upgraded to “Hold” by Zacks Investment Research

Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a sell rating to a hold rating in a research report released on Tuesday morning, Zacks.com reports.

According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

ACRX opened at $1.17 on Tuesday. The firm has a 50-day moving average price of $1.68 and a 200-day moving average price of $1.72. The company has a market capitalization of $139.17 million, a price-to-earnings ratio of -2.09 and a beta of 1.16. AcelRx Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $2.94.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings data on Sunday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.10). The business had revenue of $0.74 million during the quarter, compared to the consensus estimate of $0.75 million. On average, research analysts expect that AcelRx Pharmaceuticals will post -0.48 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the company. Credit Suisse AG purchased a new stake in shares of AcelRx Pharmaceuticals in the 4th quarter worth about $31,000. SG Americas Securities LLC purchased a new stake in shares of AcelRx Pharmaceuticals in the 4th quarter worth about $35,000. ExodusPoint Capital Management LP purchased a new stake in AcelRx Pharmaceuticals during the 4th quarter valued at about $40,000. Edmonds Duncan Registered Investment Advisors LLC grew its position in AcelRx Pharmaceuticals by 13.9% during the 4th quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 41,000 shares of the specialty pharmaceutical company’s stock valued at $89,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Dfpg Investments LLC purchased a new stake in AcelRx Pharmaceuticals during the 4th quarter valued at about $71,000. 24.45% of the stock is currently owned by hedge funds and other institutional investors.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.

See Also: How the Dogs of the Dow Strategy Works

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.